Citadel Advisors’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $68K | Buy |
|
|||||
|
2024
Q4 | – | Hold |
|
|||||
|
2024
Q3 | – | Hold |
|
|||||
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $210K | Buy |
|
|||||
|
2023
Q4 | $19.1K | Sell |
|
|||||
|
2023
Q3 | $59.5K | Sell |
|
|||||
|
2023
Q2 | $102K | Sell |
|
|||||
|
2023
Q1 | $180K | Sell |
|
|||||
|
2022
Q4 | $232K | Buy |
|
|||||
|
2022
Q3 | $168K | Buy |
|
|||||
|
2022
Q2 | – | Hold |
|
|||||
|
2022
Q1 | – | Hold |
|
|||||
|
2021
Q4 | – | Hold |
|
|||||
|
2021
Q3 | – | Hold |
|
|||||
|
2021
Q2 | – | Hold |
|
|||||
|
2021
Q1 | – | Sell |
|
|||||
|
2020
Q4 | $91K | Buy |
|
|||||
|
2017
Q2 | – | Sell |
|
|||||
|
2017
Q1 | $17K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $19K | Buy |
|